drugset / Trial / NCT04715568
Secondhand Tobacco Smoke and Cardiovascular Disease
Phase 4
Recruiting
100 enrolled
University of California, San Francisco
Flight Attendant Medical Research Institute · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.
Timeline
- Start
- 2021-03-30
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Losartan | Other / unclassified | 50 mg | Oral |